🇺🇸

Index Intelligence

· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 16, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream (broadly including retail, autos, and adjacent financials/REITs), proxy statements dominate (20+ DEF/DEFA14A) signaling annual meeting season with positive comp trends in Yum China (STI 216% payout) and Life360 (32% revenue growth), while Q1 2026 earnings reveal mixed financial performance: banks like Citizens Financial (+39% YoY NI), BancFirst (+12.3%), and Bank First (+9.9%) show robust NII growth (avg +22% YoY) post-acquisitions but NIM compression (-24 bps to -120 bps QoQ); consumer names like Hooker Furnishings report sales declines (-20.5% Q4 YoY) and impairments ($15.6M). Key trends include revenue acceleration in high-performers (TSMC +31.6% YoY, Life360 +32%) vs declines (Hooker FY -12.4%, N2OFF op loss +29%), dividend hikes (Bank First +22.2% YoY, Four Corners +3.2%), and capital raises/debt refinancings (TeraWulf $1.03B equity, Herbalife $800M notes). Critical developments: guidance cuts (Knight-Swift Q1 EPS slashed 70%), Nasdaq risks (Fathom, Smith Micro), and liquidations (NLOP portfolio down to 18 properties); implications favor financials for stability, caution retail amid weather/M&A costs, with catalysts in May/June meetings.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 16, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with broader financial crossovers), dominant themes include robust YoY Q1 2026 earnings growth in banks (avg +30% net income across Citizens, KeyCorp, BNY) contrasting QoQ softness (-2-3% revenue), a biotech funding surge (Achieve $354M, Revolution $1.65B equity +$500M notes, Alamar revenue +195% YoY), and 20+ 13F-HR filings revealing institutional portfolios overloaded with S&P 500 ETFs (e.g., iShares/Vanguard dominating 50-80% allocations) and megacap tech (Apple/NVIDIA top holdings). Healthcare-specific trends show Abbott's comparable sales +3.7% YoY but Nutrition decline -7.7% and Diagnostics weakness, offset by Exact Sciences M&A; operational metrics like Alamar's gross profit +385% YoY highlight proteomics growth outliers. Capital allocation leans shareholder-friendly with bank dividends steady ($0.46 Citizens, $0.17 South Plains) and buybacks (KeyCorp $389M, News Corp $1B program), while forward-looking catalysts cluster in May-Jun (earnings, AGMs, PDUFA). Portfolio-level patterns flag financial resilience amid rate pressures (NIM +24bps Citizens), biotech conviction via raises/appointments (Prime Medicine new CFO, Achieve new CEO), but risks in zero-revenue entities (Catalyst Crew) and cash flow swings (Grupo Galicia). Overall, actionable tilt to biotech catalysts and bank dividend stability, with 13Fs signaling passive rotation into broad indices.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 15, 2026

Across 12 filings in the USA S&P 500 Technology stream, themes emerge of mixed operational progress amid persistent cash constraints and strategic expansions in AI infrastructure, with revenue growth in niche areas like uranium (+131% YoY) and AI data centers contrasting zero-revenue tech firms like Madison Technologies. Period-over-period trends show loss narrowing in 3/12 companies (Western Uranium -29% net loss YoY, Mosaic ImmunoEngineering -25% YoY) but expanding losses and liabilities elsewhere (Madison +6.4% loss, +14% liabilities), alongside neutral 13F disclosures revealing heavy tech ETF and stock exposure (NVIDIA, Apple in top holdings). Forward-looking catalysts include BlockchAIn Digital Infrastructure's +305 MW AI capacity pipeline by 2026-2027 and AParadise Acquisition's SPAC merger closing early May 2026 with Enhanced Games launch May 24. M&A activity (Esquire S-4 merger proxy) and board enhancements (Ribbon Communications) signal consolidation, while CEO returns (Saga) and institutional holdings (Cisco's CoreWeave stake) bolster conviction. Portfolio-level patterns indicate AI-themed bets amid cash burn risks, with 4/12 filings positive on growth pipelines but 5/12 flagging liquidity woes, implying selective opportunities in infra over pure software plays.

7 high priority 5 medium 12 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 15, 2026

Across 14 SEC filings from NASDAQ-100 related entities and peers, key themes include stark contrasts in financial health: robust revenue growth in niche players like Western Uranium (+131.5% YoY) and OneMeta (massive surge from $31k to $1.5M) offset by persistent zero revenues and widening losses in development-stage firms (MDEX, LAAI, Mosaic). Capital allocation shines with Costco's 13% dividend hike signaling confidence, while operating losses narrowed in mining (Western) and immunoengineering (Mosaic) amid cost cuts. Institutional 13F filings (Wealth Intelligence, Cisco, Murphy Middleton) reveal concentrated ETF/large-cap bets with neutral sentiment, no major shifts. Positive management updates (Saga CEO return, Ribbon board addition, IPM post-acquisition growth) contrast going concern warnings and cash burn. Portfolio-level trends show 4/7 10-Ks with revenue growth or stability but universal net losses, liabilities rising in 4 cases (avg +30% YoY), highlighting high-risk turnaround potential in small caps vs. stability in retail/broadcasting. Upcoming catalysts cluster in May 2026 (mergers, AGMs, dividends, events) offer timed alpha amid mixed sentiment (7 mixed/negative).

9 high priority 5 medium 14 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 15, 2026

Across 50 filings in the USA S&P 500 Financials stream (broadly including banks, insurers, asset managers, REITs, and advisors), sentiment is predominantly neutral-to-mixed, with 13F filings from 14 asset managers/advisors revealing heavy ETF allocations (e.g., S&P 500, QQQ, broad market) signaling defensive positioning amid market highs. Financial performers like M&T Bank showed resilient YoY EPS growth (+24% to $4.13) and NIM expansion to 3.71% despite QoQ softness and CRE loan declines (-11% YoY), while Chunghwa Telecom (adjacent financial services exposure) guided capex up to NT$31.9B for 2026 (+15% YoY). Capital allocation trends favor buybacks (M&T $1.25B, News Corp $1B program) and dividends (Chunghwa NT$5.20/share), but smaller names face dilution risks from offerings (TeraWulf $900M, Soluna SEPA) and Nasdaq compliance issues. M&A activity (Mission/Calavo merger taxes capped at $5M, Galera/Obsidian all-stock deal) and leadership shifts (World Acceptance interim CEO) highlight restructuring, with portfolio-level margin pressures in 4/6 reporting firms (avg efficiency ratio up 300bps). Key implication: Banks stable but watch CRE/nonaccruals; advisors bullish on mega-caps/ETFs; alpha in merger catalysts and cost-cutters like Snap ($500M savings runway).

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 15, 2026

Across 50 SEC filings from the S&P 500 Consumer Staples stream (broadened to related sectors), sentiment is predominantly neutral/mixed with pockets of positive capital returns and negative operational pressures; key period-over-period trends show modest revenue growth averaging 3-5% YoY in reporting firms like Selectis Health (+5%), Chunghwa Telecom (+2.7%), and Cosmofarm (+15% wholesale), but sharp declines in others like Sotherly Hotels (-3% revenue, -38.5% NOI) and heavy losses in biotechs/REITs. Dividend hikes signal shareholder focus in staples (Costco +13% to $1.47/share, Chunghwa NT$5.20/share), contrasting with rising debt and liquidity strains (Strawberry Fields $752M debt, Selectis senior notes +55% to $1.59M). Executive appointments (Regis, Prelude Therapeutics) and JV deals (Limoneira composting) highlight strategic pivots, while prelim guidance holds firm despite Q1 softness (QuidelOrtho $615-620M revenue). Portfolio-level patterns reveal margin compression in hospitality/healthcare (avg -200bps+ in Sotherly/Selectis) vs. EPS gains in industrials (PPG +6%, nVent +35%), with capex upticks (Chunghwa +15% to NT$31.9B 2026) pointing to infrastructure bets. Market implications favor defensive staples amid volatility, with catalysts like May earnings/AGMs driving near-term moves.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 15, 2026

Across 50 filings in the USA S&P 500 Industrials intelligence stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors like energy/utilities), dominant themes include robust M&A/SPAC activity (e.g., BOXABL $3.5B merger, Pantages amendment, Aspire $30M LOI), debt refinancings/extensions (Basin Electric $700M exchange, US Physical Therapy credit amend), and mixed bank earnings spillovers impacting industrial financing (BofA +17% YoY NI, M&T +14% YoY NI but QoQ declines). Period-over-period trends reveal revenue growth in select names (Barfresh +33% YoY to $14.2M, BofA +7% YoY) offset by declines (Tradewinds -22% YoY, Edenor residential -1.6% YoY, M&T NII -2% QoQ), with margin pressures evident (Barfresh gross profit -15% YoY, M&T efficiency ratio 58.3% vs 55.1% QoQ). Capital allocation leans toward buybacks (M&T $1.25B repurchase) and equity raises (Tradewinds ~$1.17M), while forward-looking catalysts cluster in H2 2026 (Pasqal Nasdaq listing, Barfresh new facility operational). 13F-HR filings (17 instances) show institutional conviction in industrials-adjacent like AAR Corp, WW Grainger, FedEx via diversified portfolios. Sentiment skews neutral/mixed (28/50), with positive outliers in quantum/tech M&A and FDA designations signaling innovation alpha. Portfolio-level implication: Industrials poised for M&A-driven upside amid financing stability, but watch margin compression in ops-heavy firms.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 15, 2026

Across 8 filings in the USA S&P 500 Energy intelligence stream, Hallador Energy Co (HNRG) dominates with bullish executive compensation enhancements, including CEO salary up 18.5% YoY to $800k and $68M 2026 Adj EBITDA target, alongside proxy filings for May 27 AGM highlighting 17.43% insider ownership. Other filings reveal mixed capital-raising activities, with Bioxytran narrowing net losses 10% YoY to $2.1M via G&A cuts (sales/marketing down 81% to $64.5k) but highly dilutive 20M+ share issuances at $0.025/share, and Zapata Quantum raising $3.75M in Series D toward $15M total. SPAC developments include Hall Chadwick's sponsor protections and AParadise's merger registration effective, targeting early May 2026 NYSE listing as $ENHA. No broad sector margin compression or revenue trends emerge due to non-operational focus, but period comparisons show cost discipline in Bioxytran and positive sentiment in raises/comp. Key implications: HNRG signals management conviction in coal/energy ops; dilution risks in microcaps; catalysts cluster in late May 2026. Portfolio theme: Selective bullishness in legacy energy (HNRG) amid SPAC/tech crossovers.

5 high priority 3 medium 8 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 15, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily blue-chip influenced but inclusive of sector peers), banking giants like Bank of America, PNC, and M&T demonstrate robust YoY growth with net income up 17%, 18%, and 14% respectively, driven by deposit/loan expansion (BAC +3% deposits, +9% loans; PNC +4% deposits, +7% loans) and NIM stability/expansion, signaling sector resilience amid acquisitions like PNC's FirstBank. Small-cap biotech/food/tech firms show mixed results: revenues volatile (Vivakor segments -84% to +87% YoY; Veea +57%), losses widening (CERO +140% net loss; Eightco massive $262M loss), offset by funding/dilution (Soluna SEPA $25M potential). M&A activity accelerates positively (Leidos JV $625M revenue contrib; Viant $40M TVision buy), while proxies flag routine governance (BRFH share increase, annual meetings June). 13F filings (20+) reveal institutional conviction in mega-caps/ETFs (MSFT/AAPL/NVDA ubiquitous; total AUM $10B+), but small caps face dilution/Nasdaq risks (Soluna delisting notice). Overarching: Banks outperform (avg +15% YoY NI), small caps underperform (avg revenue flat/declining, losses up), with catalysts in H2 M&A/earnings. Portfolio implication: Overweight banks, monitor small-cap turnarounds, hedge via 13F-tracked ETFs.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 15, 2026

Across 50 filings primarily from financials, tech, SPACs, and REITs (despite Consumer Discretionary focus), Q1 2026 bank earnings show robust YoY growth (e.g., Bank of America NI +17%, revenue +7%; PNC NI +18% YoY) but mixed QoQ trends (First Horizon flat NI QoQ, PNC NII +6% QoQ offset by rising provisions). Debt issuances dominate for M&A, buybacks, and ops (TransDigm $1.5B for Stellant acq + $800M buybacks; Marvell $1B notes), signaling confidence in growth amid high leverage. SPAC/post-merger activity surges (Merlin S-1 for 66M+ shares, BOXABL S-4/A at $3.5B val, Pasqal H2 2026 Nasdaq via Bleichroeder), with positive funding/tech milestones. Capital allocation favors returns (OceanFirst $0.20 div, TransDigm buybacks) over cuts. 13F-HRs (20+ filings) reveal ETF-heavy portfolios (Vanguard S&P, tech giants) with no major shifts, indicating stability. REIT risks highlight concentration (Strawberry Fields 86.8% rent from 15 related leases). Forward catalysts cluster in Apr-May (debt closings, earnings), positioning tactical opportunities in financials/SPACs amid stable asset quality.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 15, 2026

Across 50 filings in the S&P 500 Healthcare stream (though including cross-sector context via 13F holdings), dominant patterns emerge from 25+ 13F-HR disclosures showing institutional portfolios heavily weighted to mega-cap tech (AAPL, MSFT, NVDA averaging top 3 holdings at 10-25% allocation) and broad ETFs (e.g., SCHB, SPY), indicating conviction in resilient large-caps amid Q1 2026 positioning. Healthcare-specific highlights include Amgen's robust 10% YoY revenue/sales growth with 18 products at record sales and 14 exceeding $1B, Wave Life Sciences' redomiciliation to Delaware mid-2026 for cost savings, and Integra Lifesciences' $150M A/R facility extension to 2029 signaling liquidity strength. Period-over-period trends show mixed small-cap results (e.g., Citi Trends sales +8.9% YoY to profitability vs Tradewinds revenue -22% YoY, op ex +368%), while financials like PNC posted NII +6% QoQ/loans +7% but rising provisions/charge-offs. Capital allocation favors dividends (6 declarations/hikes, e.g., Costco +13% to $1.47/share), with limited buybacks beyond News Corp's $1B program. Proxies dominate (15+ DEF/DEFA14A) with equity plan expansions (Neurocrine +4M shares) and auditor ratifications; no major insider personal trades but institutional holdings stable. Key implication: Healthcare biotechs/pharma show operational strength amid sector restructuring, while broader filings flag dividend yield opportunities and tech overweight risks.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 14, 2026

Across 14 filings in the USA S&P 500 Technology stream, overarching themes include steady institutional portfolios (5/14 are 13Fs with no reported changes, heavy ETF and select tech exposure like Intel at $5.7B in Murphy Pohlad), governance shifts (board refreshes at ImmuCell, bylaw amendments at GameSquare, reverse split at Immunic), and mixed financials in non-core holdings (revenue declines at Saga Communications -5.1% YoY, loss narrowing at Bravo -41% expense cut). Period-over-period trends show deterioration in select areas: Saga's net operating revenue down 5.1% YoY to $107M with full goodwill impairment to $0, Bravo cash down 61% YoY to $111 amid 32% liability rise, but station expenses flat -0.1% at Saga. Critical developments include AParadise SPAC merger progress with Enhanced Ltd at $1.2B EV and May 1 meeting, ImmuCell's positive board bolstering animal health innovation, and Immunic's 1-for-10 reverse split effective April 27. Portfolio-level patterns reveal institutional conviction in tech outliers like Intel ($5.7B top holding) and Cisco ($1.5M), contrasting bearish signals from impairments and cash drains, signaling selective opportunities amid governance catalysts in May-June 2026.

6 high priority 8 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 14, 2026

Across 17 SEC filings from NASDAQ-100 stream companies and related entities on April 14, 2026, dominant themes include corporate governance shifts (Meta directors departing, ImmuCell board refresh with new Strategy Committee), high-profile M&A (Amazon's acquisition of Globalstar, AParadise SPAC merger with Enhanced at $1.2B EV), and mixed annual results (Saga revenue -5.1% YoY to $107M with $20M+ impairments driving net loss -$1.22 EPS vs +$0.55 prior; Bravo net loss improved 36% YoY to -$253K via 41% expense cuts but cash -61% to $111). Institutional 13F-HRs reveal stable, diversified ETF-heavy portfolios (e.g., Murphy Pohlad $279B AUM with Intel/Chevron tops, no changes noted). Period-over-period trends show media weakness (Saga flat expenses but market share dips in Milwaukee/Columbus) contrasting small-cap cost discipline (Bravo G&A -77% YoY); no broad insider trading signals but board changes signal potential strategy pivots. Forward catalysts cluster in May-June (SPAC votes, reverse splits, AGMs), with Amazon M&A implying telecom expansion amid neutral-to-positive sentiments (9/17 positive/mixed). Portfolio implications: Watch tech M&A for upside, media impairments for downside risks, governance for conviction gauges.

9 high priority 8 medium 17 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 14, 2026

Across 50 diverse SEC filings labeled under USA S&P 500 Financials (though spanning energy, healthcare, biotech, and industrials), key themes include a surge in M&A/takeover activity with attractive premiums (e.g., Avanos +72%, Day One $21.50/share), mixed Q1/FY results showing YoY revenue gains in banks like Wells Fargo (+6%) and Unity Bancorp (+12.8% NII) but QoQ softness and rising provisions, and neutral 13F holdings with no major shifts. Period-over-period trends reveal 6/12 earnings filings with YoY net income growth (avg +10%) offset by margin compression in 5/10 (avg -150bps, e.g., AstroNova -7.4% gross profit), while capital allocation favors dividends/buybacks (Unity +7%, Wells $4B repurchase). Forward-looking catalysts cluster in H2 2026 M&A closings and energy transition deals (DevvStream/XCF targeting $1B revenue). Portfolio-level, financials show loan/deposit growth (Unity +10.9%/+YoY) but credit provisions spiking (Wells +1095% YoY), signaling caution amid stable charge-offs. Implications: Tactical M&A arbitrage opportunities, monitor bank NIM/provisions, flat institutional conviction per 13Fs.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader financial and operational crossovers), dominant themes include strong YoY revenue and net income growth in major financial institutions like JPMorgan (+13% NI, +10% revenue), BlackRock (+27% revenue, $130B inflows), and Wells Fargo (+7% NI, +15% EPS), offset by rising credit provisions (Wells +1093% YoY) and mixed segment results. Consumer Staples highlights feature stable capital returns from Procter & Gamble (quarterly dividend $1.0885, record date Apr 24) and Hershey (exec departure neutral), alongside Celsius Holdings' steady 8.6-8.97% insider ownership amid proxy battles. Small-cap operators show sharp declines, e.g., Greystone Logistics sales -45% YoY 9M to $22M, Nature's Miracle revenue -97.6% YoY Q3, and Chipmos net profit -61.7% YoY amid margin compression to 10.8%. Portfolio-level trends reveal 4/7 key financial reporters with +6-27% YoY revenue growth but 3/5 with margin/operating pressures; capital allocation favors dividends (P&G, BlackRock +10%) and buybacks (Wells $4B, BlackRock $450M). Board/governance changes prevalent in 12/50 filings (e.g., appointments at ImmuCell, Invesco Mortgage), signaling strategic shifts. Actionable implications: Favor large-cap financials with consumer exposure for growth, monitor staples leadership stability and small-cap restatements for downside risks.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Industrials stream, 13F-HR reports dominate (e.g., Regent Peak, Runnymede, multiple American State Bank filings), revealing a portfolio-level pattern of heavy concentration in non-industrial mega-caps like Nvidia (top holding in 10+ filers, values up to $21.5M), Apple, and Microsoft, signaling institutional conviction in tech proxies amid industrial sector caution. Company-specific filings show mixed period-over-period trends: revenue growth in select areas (Heritage Distilling +20.4% YoY total net revenues, Unity Bancorp loans +10.9% YoY) contrasted by declines (Saga Communications -5.1% YoY revenue, Alphega net loss +92% YoY) and cash flow volatility (Antalpha financing cash -86% YoY). M&A activity surges in industrials-adjacent spaces like robotics (Serve Robotics acquisition complete, AgEagle $10M JV in counter-drones) and renewables (XCF Global/DevvStream/Southern merger targeting $1B revenue), with positive sentiment. Capital allocation mixed: dividend hikes (Unity +7% to $0.16, Ohio Valley $0.25) vs cuts (Saga -37.5% to $1.00). Forward-looking catalysts cluster in Q2 2026 AGMs (REGENXBIO May 29, Northrim May 28, ImmuCell June 11) and merger milestones (XCF $400M bonds, $1B revenue by Jun 30). Overall neutral-mixed sentiment (20+ neutral 13Fs), with actionable alpha in M&A execution risks and tech-tilted industrials exposure.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 14, 2026

Across the USA S&P 500 Energy intelligence stream, six filings highlight mixed sentiment dominated by operational volatility in APA Corp's preliminary 1Q26 results, showing robust international oil prices at $85.70/bbl and a $244M pre-tax net gain on purchases/sales, contrasted by negative US natural gas prices at $(0.35)/Mcf triggering 88 MMcf/d gas and 6,800 bbl/d NGL curtailments. OKMIN Resources reports a merger termination setback but secures $54k via dilutive private placement, while SunCoke Energy issues minor proxy corrections ahead of its May 14 AGM. Non-core filings include Silchester International's stable 13F-HR with $115.6B portfolio heavily tilted to non-energy names like Nutrien ($98.8B position), and AParadise Acquisition Corp's advancing $1.2B SPAC merger with Enhanced Ltd toward a May 1 vote and NYSE listing as ENHA. Limited period-over-period data reveals no broad YoY/QoQ trends across the group, but APA's elevated $115M G&A (incl. $25M higher stock-based comp) and $66M commodity derivative losses signal cost pressures amid price swings. Portfolio-level patterns point to May catalyst clustering (earnings, AGMs, votes) and M&A turbulence, with implications for near-term volatility in energy production and services amid US gas weakness versus international oil resilience.

3 high priority 3 medium 6 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 14, 2026

Across 50 filings dated April 14, 2026, for the USA Dow Jones 30 stream, institutional 13F-HR reports (25+ filings) reveal overwhelming conviction in mega-cap tech with NVDA, AAPL, MSFT, and AMZN comprising top holdings in $100B+ portfolios, signaling sustained bullish bias amid no reported changes QoQ. Blue-chip earners show resilience: JNJ Q1 sales +9.9% YoY (raised FY2026 guidance to $100.8B, +7%), JPM net income +13% YoY ($16.5B), but mixed EPS/FCF trends (JNJ GAAP NI -52%). Healthcare catalysts dominate with Travere's first-ever FSGS FDA approval (46% proteinuria cut) and Avanos $1.27B buyout at 72% premium; energy M&A surges via XCF/DevvStream/Southern merger targeting $1B rev by Jun 30. Small caps flash distress: Hydrofarm loan forbearance post-default, Alphega loss +92% YoY, American Battery ICFR weaknesses. Capital allocation favors dividends (Unity +7%, Dow 459th consecutive $0.35, Ohio Valley $0.25). Portfolio trends: Revenue +10-20% YoY avg in reporters, but margins mixed (-7% gross AstroNova); DJ30-exposed names (JNJ, JPM, DOW) outperform small caps, implying buy blue-chips, avoid distressed.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 14, 2026

Across 50 SEC filings from April 14, 2026, primarily non-Consumer Discretionary but including financials, energy, tech, and SPACs, key themes emerge in M&A activity (7 deals with positive/mixed sentiment), stable institutional 13F holdings heavily tilted to ETFs/tech (9 filings showing no changes), and mixed financial performance with revenue growth in 5/12 reporting companies (avg +27% YoY) offset by widening losses in development-stage firms. Period-over-period trends show YoY revenue gains (e.g., Full Truck Alliance +11.1%, Digital Brand Media +40.1% Q1) but margin pressures and rising provisions (Wells Fargo provisions +1094% YoY to $11.1B); capital allocation leans positive with dividend hikes (FNB +8%) and buybacks ($250M new program). Critical developments include merger closures (Horizon Technology positive) and distress signals (Hydrofarm forbearance, Gulf Resources 10-K delay), implying opportunities in consolidations but risks in liquidity-constrained names. Portfolio-level patterns: 6/10 financial filings bullish on returns to shareholders, contrasting negative debt events in 3 energy/industrials; no S&P 500 Consumer Discretionary pure-plays but cross-sector insights flag M&A as a growth driver amid stable institutional conviction.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 14, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, healthcare-specific insights reveal mixed Q1 2026 performance with Johnson & Johnson posting 9.9% YoY sales growth but 52.4% GAAP EPS decline, offset by raised FY2026 guidance (sales +7.0%, EPS +7.1%); biotech sector shows M&A momentum (Kezar tender at $6.955/share + CVR) and catalysts (Praxis NDA accepted, PDUFA Jan 29 2027). Aggregate trends indicate revenue acceleration in pharma (JNJ +9.9%, BeOne +40.2% YoY to $5.343B) but widening losses in pre-clinical biotechs (Accustem net loss +16.7% to $1.756M). Non-healthcare filings dominate (31/50 are 13F-HR neutral snapshots heavy in ETFs/tech like Apple/MSFT/NVDA, no changes), signaling advisor caution or stability; capital raises proliferate (Lucid $550M, Cingulate resale registration). Portfolio-level: 5/10 key healthcare firms raised/reiterated guidance, but 4/10 reported margin dips or expense surges (e.g., New Horizon R&D +867% YoY). Critical implications: Biotech alpha from catalysts/M&A, but dilution risks in small caps; watch advisor 13Fs for healthcare rotations.

12 high priority 38 medium 50 total filings